Search research articles
Contact Us
Filters
Showing results (11-20 of 34) with videos related to
Page
of 4
Sort By:
Advances in Therapy
|
July 28, 2019
Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
Tereza Lanitis, Irina Proskorovsky, Apoorva Ambavane, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 23, 2018
Modeling Clinical Outcomes in Prostate Cancer: Application and Validation of the Discrete Event Simulation Approach
Feng Pan, Odette Reifsnider, Ying Zheng, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 4, 2009
Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial
Thitima Kongnakorn, Alexandra Ward, Craig S Roberts, et al.
Health and Quality of Life Outcomes
|
March 13, 2014
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma
Irina Proskorovsky, Philip Lewis, Cathy D Williams, et al.
Journal of Market Access & Health Policy
|
June 14, 2021
Modeling long-term health and economic implications of new treatment strategies for Parkinson's disease: an individual patient simulation study
Conor Chandler, Henri Folse, Peter Gal, et al.
Journal of Medical Economics
|
June 19, 2015
Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US
Catherine Saint-Laurent Thibault, Ipek Özer Stillman, Stephanie Chen, et al.
Cancer
|
December 7, 2018
Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: Results from LATITUDE
Tracy Li, Conrado Franco-Villalobos, Irina Proskorovsky, et al.
Advances in Therapy
|
March 22, 2023
Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
Christopher Parker, Fei Fei Liu, Kristen A Deger, et al.
Contemporary Clinical Trials Communications
|
December 5, 2024
Modeling severe uncontrolled asthma: Transitioning away from health states
Tereza Lanitis, Asif H Khan, Irina Proskorovsky, et al.
Circulation
|
December 23, 2009
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38
Elizabeth M Mahoney, Kaijun Wang, Suzanne V Arnold, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 34) with videos related to
Sort By:
Page
of 4
Advances in Therapy
|
July 28, 2019
Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
Tereza Lanitis, Irina Proskorovsky, Apoorva Ambavane, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 23, 2018
Modeling Clinical Outcomes in Prostate Cancer: Application and Validation of the Discrete Event Simulation Approach
Feng Pan, Odette Reifsnider, Ying Zheng, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 4, 2009
Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial
Thitima Kongnakorn, Alexandra Ward, Craig S Roberts, et al.
Health and Quality of Life Outcomes
|
March 13, 2014
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma
Irina Proskorovsky, Philip Lewis, Cathy D Williams, et al.
Journal of Market Access & Health Policy
|
June 14, 2021
Modeling long-term health and economic implications of new treatment strategies for Parkinson's disease: an individual patient simulation study
Conor Chandler, Henri Folse, Peter Gal, et al.
Journal of Medical Economics
|
June 19, 2015
Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US
Catherine Saint-Laurent Thibault, Ipek Özer Stillman, Stephanie Chen, et al.
Cancer
|
December 7, 2018
Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: Results from LATITUDE
Tracy Li, Conrado Franco-Villalobos, Irina Proskorovsky, et al.
Advances in Therapy
|
March 22, 2023
Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
Christopher Parker, Fei Fei Liu, Kristen A Deger, et al.
Contemporary Clinical Trials Communications
|
December 5, 2024
Modeling severe uncontrolled asthma: Transitioning away from health states
Tereza Lanitis, Asif H Khan, Irina Proskorovsky, et al.
Circulation
|
December 23, 2009
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38
Elizabeth M Mahoney, Kaijun Wang, Suzanne V Arnold, et al.
Page
of 4